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Summary
BACKGROUND: High-dose chemotherapy (HDCT) with
autologous stem cell transplantation (ASCT) has been re-
ported to confer better prognosis in systemic light chain
AL-amyloidosis as compared with conventional chemo-
therapy. However, only limited data are available so far
on treatment and outcome of AL-amyloidosis patients in
Switzerland.
METHODS: Within a single-centre cohort of patients with
biopsy confirmed AL-amyloidosis diagnosed between
January 1995 and December 2012, we aimed to investigate
treatment effects in patients treated with conventional
chemotherapy versus HDCT with ASCT.
RESULTS: We identified 50 patients with AL-amyloidosis
treated with conventional chemotherapy and 13 patients
who received HDCT with ASCT. Clinical characteristics
differed between the groups for the age of the patients
(59 years for patients with ASCT/HDCT vs 69 years; p=
0.0006) and the troponin-T value (0.015 μg/l vs 0.08 μg/l; p
= 0.0279). Patients with ASCT showed a trend towards bet-
ter overall survival, with median survival not yet reached
compared with 53 months in patients on conventional
chemotherapy (p = 0.0651).
CONCLUSION: Our results suggest that light chain AL-
amyloidosis patients considered fit to undergo HDCT and
ASCT may have a better outcome than patients treated
exclusively with conventional chemotherapy regimens;
however, the better performance status of patients receiv-
ing HDCT may have added to this treatment effect.
Key words: amyloidosis; autologous transplant; high-dose
chemotherapy; troponin; light chain
Introduction
Systemic AL-amyloidosis (AL) is a rare clonal plasma cell
disorder, which is characterised by the deposition of ab-
errant amyloid protein derived from monoclonal immuno-
globulin light chains in a broad variety of soft tissues [1–3].
Although the burden of plasma cells is generally low, the
accumulation of the pathogenic amyloid deposits in the
heart, kidneys, liver, gastrointestinal tract or nerves may
cause substantial morbidity and may lead to rapidly pro-
gressive organ failure and ultimately death [4–5].
The prognosis of patients with AL-amyloidosis largely de-
pends on the type and severity of organ involvement, in
particular on cardiac involvement [6–7]. Consequently, the
current revised prognostic staging system for patients with
light chain AL-amyloidosis is based on two cardiac bio-
markers – troponin-T and N-terminal-pro-B-type natriuret-
ic peptide (NT-ProBNP) – and on the level of the amyl-
oidogenic light chain synthesis, which largely determine
prognosis, but also affect therapeutic options for amyl-
oidosis patients [8].
The introduction of high-dose chemotherapy (HDCT) with
autologous stem cell transplantation (ASCT) has improved
the outcome of some AL-amyloidosis patients when com-
pared with conventional chemotherapy regimens [9–15].
HDCT with ASCT was reported to confer improved overall
survival, particularly in amyloidosis patients achieving a
complete remission [16–19], and it has also been associated
with improved quality of life [20]. However, a majority of
patients with systemic light chain AL-amyloidosis are not
considered fit enough to undergo ASCT because of limit-
ing organ involvement [21–24]. Therefore, careful patient
selection is crucial to identify amyloidosis patients most
likely to benefit from ASCT and to minimise the histor-
ically excessive transplant-related mortality of AL-amyl-
oidosis patients [25–26].
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Only few data on treatment and outcome of AL-amyl-
oidosis patients in Switzerland are available so far [27].
Therefore, the aim of this study was to examine a single-
centre cohort of patients with light chain amyloidosis and
to compare the outcome of patients treated with conven-
tional chemotherapy with those treated with HDCT and
ASCT. Such a cohort may hopefully be extended at a sub-
sequent stage to initiate a Swiss cohort of AL-amyloidosis
patients.
Study design
Patients
Patients with systemic light chain AL-amyloidosis dia-
gnosed between January 1995 and December 2012 at the
Department of Clinical Oncology at the University Hospit-
al in Bern, Switzerland, were included in this retrospect-
ive study. Consecutive patients were identified by keyword
searching in all databases of this single centre. Patients
were required to have a representative tissue biopsy with
Congo-red and immunohistochemical staining confirming
AL-amyloid disease. The diagnosis of light chain amyl-
oidosis required a documented plasma cell dyscrasia,
which was diagnosed by the presence of a clonal plasma
cell population in the bone marrow and/or monoclonal
gammopathy detected by immunofixation electrophoresis
of serum or urine proteins [3, 28–30]. Patients with famili-
al, senile, localised or other forms of amyloidosis were not
included in this study [3]. Diagnosis of organ involvement,
response to treatment and disease progression were defined
according to the international consensus guidelines [31].
For conditioning before ASCT, patients received a total
dose of 200 mg/m2 melphalan.
Statistical analysis
This was an observational study. The study population was
divided into two groups, comprising patients treated with
conventional chemotherapy or with HDCT and ASCT, rep-
resenting the two basic therapeutic options for amyloidosis
patients. The two groups were compared for differences in
clinical characteristics at diagnosis and in outcome. Overall
survival was defined as the time from the date of diagnos-
is until death or last follow-up, whichever occurred first.
Figure 1A
Overall survival of all AL-amyloidosis patients. The median overall
survival of the entire study population was 133 months. Twenty-four
patients died. X-axis indicates months, and Y-axis percent survival.
The time until first progression was the time from diagnos-
is until first progression or death, whichever occurred earli-
er, or until last follow-up if patients remained in remission.
Curves depicting overall survival and time to progression
were plotted using the Kaplan-Meier method. The surviv-
al estimates in the two groups were compared using the
log-rank test, and differences in the mean values of con-
tinuous variables were tested using the t-test. All statistical
analyses and graphs were performed using graph pad prism
program 5.04 (1992–2010 GraphPad Software, Inc., NC,
USA).
Results
We identified 63 patients with systemic light chain amyl-
oidosis, 44 patients having primary AL-amyloidosis and 19
patients having secondary AL-amyloidosis due to multiple
myeloma or Waldenström’s macroglobulinaemia. Patients
were assigned to either one group including patients treated
with conventional chemotherapy regimens (n = 50), or a
second group including patients who underwent HDCT
with ASCT (n = 13). The reasons not to proceed to HDCT
with ASCT were age (n = 12; 24%), relevant organ dys-
Figure 1B
Overall survival of patients treated with HDCT/ASCT (continuous
line) versus conventional chemotherapy (dotted line). The HDCT/
ASCT showed a trend toward better overall survival (p = 0.0651).
The HDCT/ASCT group had not yet reached median overall
survival, whereas the median overall survival of the conventional
chemotherapy group was 53 months.
ASCT = autologous stem cell transplantation; HDCT = high-dose
chemotherapy
Figure 1C
Time to progression (TTP) of the entire study group. Median TTP
was 39 months, and 36 patients had progression of their disease.
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function (n = 14; 28%) and multiorgan failure (n = 19;
38%). Five patients (10%) declined HDCT with ASCT.
Within the entire cohort of 63 patients, the two groups
showed no differences with regards to sex, blood cell
counts, BNP, β2–microglobulin, albumin, type and level
of gammopathy (typically with intact immunoglobulin and
associated light chain disease), proteinuria, creatinine and
level of malignant plasma cell infiltration in the bone mar-
row at initial diagnosis. However, patient characteristics
differed for age (p = 0.0006) and troponin-T levels (p =
0.0279), two parameters well known to be associated with
outcome of AL-amyloidosis patients. The mean level of
free light chains at diagnosis was 740 mg/l for the entire
study group, 1652 mg/l in the HDCT/ASCT group and
355 mg/l in the conventional chemotherapy group (p =
0.1039). Five patients in the group with HDCT/ASCT had
a first-line treatment before HDCT/ASCT, whereas the oth-
er eight patients directly proceeded to the high-dose treat-
ment. For the conventional chemotherapy group, the vari-
ous regimens are listed in table 1. Clinical characteristics
at diagnosis, laboratory values at initial presentation, types
of therapy, and the course of the disease of the entire study
population are also summarised in table 1.
At diagnosis, a total of 38 patients (60%) had cardiac in-
volvement as assessed with echocardiography, 35 patients
(56%) had renal involvement, 17 patients (27%) had nerve
involvement and 5 patients (8%) had liver involvement.
Other organs involved included lung, intestine, spleen,
larynx or tongue. Forty-eight percent had one organ in-
volved, 30% had two-organs disease, 19% had three organs
involved and 3% had four- (or more) organ disease. The
conventional chemotherapy group had a higher percentage
of cardiac involvement than the HDCT/ASCT group (66%
vs 38%).
After a mean follow-up of 31 months for the entire cohort
at the cut-off day on 31 December 2012, one death (7.7%)
occurred in the HDCT/ASCT group, and 23 deaths (46%)
in the conventional chemotherapy group (p = 0.0116). The
single death in the HDCT/ASCT group was transplant re-
lated, and it occurred at day 10 after ASCT; thus the
transplant-related mortality of the HDCT/ASCT cohort
was 7.7%.
The median overall survival of the entire cohort was 133
months (fig. 1A). Patients undergoing HDCT/ASCT had
a trend towards better overall survival compared with the
conventional chemotherapy group (p= 0.0651, fig. 1B, haz-
ard ratio 0.3694, 95% confidential interval 0.1282‒1.064).
The p-value did not reach significance, most likely because
of the small cohort size. The HDCT/ASCT group had not
yet reached the median survival, whereas the conventional
chemotherapy group had a median survival of 53 months.
Of the entire study population, 36 patients had disease pro-
gression (fig. 1C), with four patients (31%) in the HDCT/
ASCT group and 32 patients (64%) in the conventional
chemotherapy group (p = 0.0566, fig. 1D). The median
time to progression (TTP) of the entire study population
was 19 months, with the median TTP not yet reached in the
HDCT/ASCT group, and 15 months in the group with con-
ventional chemotherapy (p = 0.248, hazard ratio 0.6012,
95% confidential interval 0.2536-1.425).
Discussion
Only few data are available so far on treatment and out-
come of AL-amyloidosis patients in Switzerland. In par-
ticular, one single-centre study reported experience with
16 patients with AL-amyloidosis treated with HDCT and
ASCT [27]. In this study, we report a single-centre cohort
of 63 patients in the period from January 1995 to December
2012, diagnosed and treated at the Department of Clinical
Oncology and Institute of Pathology at the University Hos-
pital and University of Bern, Switzerland. The study pop-
ulation was divided into a group of patients treated with
HDCT/ASCT and a second group comprising patients un-
dergoing conventional chemotherapy. We found that amyl-
oidosis patients receiving HDCT and ASCT tended to have
a more favourable outcome than patients treated with con-
ventional chemotherapy (p = 0.0651).
Previous reports have suggested that response rates and
overall survival are better in systemic AL-amyloidosis pa-
tients treated with HDCT/ASCT as compared with con-
ventional chemotherapy regimens [9–13]. However, only a
minority of amyloidosis patients, usually those with lim-
ited organ disease and/or those lacking significant cardiac
involvement, are eligible for HDCT/ASCT [8]. In contrast,
a single randomised study failed to show a benefit for
HDCT/ASCT compared with oral melphalan and dexa-
methasone [32]; however, 26% of the patients in the trans-
plantation arm of this multicentre study ultimately did not
receive HDCT/ASCT, and the ASCT treatment-related
mortality was excessive (24%). The baseline patient char-
acteristics in this randomised trial were equally balanced
between the two groups, with a similar organ involvement
and age as the HDCT/ASCT group in our study [32].
Our data from systemic AL-amyloidosis patients indicate
a trend toward better overall survival for patients undergo-
ing HDCT/ASCT: the median survival was not reached in
the HDCT/ASCT group versus 53 months in the conven-
tional chemotherapy group (p = 0.0651). The two groups of
this cohort differed significantly in two clinical character-
istics: patients undergoing HDCT/ASCT were younger (59
vs 70 years, p = 0.0006), and their troponin-T values were
Figure 1D
Time to progression (TTP of) patients treated with HDCT/ASCT
(continuous line) versus conventional chemotherapy regimens
(dotted line). The HDCT/ASCT group had not yet reached the
median TTP; the TTP of the conventional chemotherapy group was
15 months (p = 0.248).ASCT = autologous stem cell
transplantation; HDCT = high-dose chemotherapy
Original article Swiss Med Wkly. 2014;144:w13922
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 8
Table 1: Characteristics of the study population.
HDCT/ASCT Conventional
chemotherapy
All p-value
n 13 50 63
Age mean ± SEM
range
59.2 ± 1.7
62–69
69.6 ± 1.4
45–93
67.4 ± 1.3
45–93
<0.0001
Sex male/female 5/8 33/17 38/25 0.1107
Troponin-T (µg/l)(×) mean ± SEM
range
0.015 ± 0.004
0.003–0.034
0.08 ± 0.03
0.001–0.369
0.081 ± 0.024
0.001–0.369
0.0279
BNP (ng/l)(°) mean ± SEM
range
240 ± 102
19–978
5252
124–40000
3104
19–40000
0.1983
β2-microglobulin (mg/l) (§) mean ± SEM
range
2.9 ± 0.8
1.4–11.2
6 ± 1.3
1.8–28
4.9 ± 0.95
1.4–28
0.1182
Albumin (g/l) (¨) mean ± SEM
range
31.5 ± 2.3
14–43
31.3 ± 1.3
5–43
31.4 ± 1.1
5–43
0.9380
Light chain (*) kappa/lambda 5/7 15/34 20/41 0.5050
Light chain value (mg/L) (Y) mean ± SEM
range
1652
11.8–13631
355 ± 67
2.7–1098
740
2.7–13631
0.1039
Subtypes IgG
IgA
IgM
light chain only
3
3
1
6
14
4
5
27
17
7
6
33
Paraprotein value (g/l) ($) mean ± SEM
range
17.3 ± 5.4
5.6–36.9
15.1 ± 1.6
2.7–22.3
15.6 ± 1.8
2.7–36.9
0.5892
Proteinuria (g/l) yes/no
mean ± SEM
range
8/5
2.9 ± 1
0.3–6.8
25/25
2.9 ± 0.4
0.14–6
33/30
2.9 ± 0.4
0.14–6.8
0.5423
0.9765
Haemoglobin (g/l) mean ± SEM
range
136 ± 4.2
96–153
122 ± 3.4
82–181
125 ± 2.9
82–181
0.0529
Leucocytes (G/l) mean ± SEM
range
7.6 ± 0.4
5.2–10.8
8 ± 0.4
4.1–17
7.9 ± 0.3
4.1–17
0.5540
Platelets (G/l) mean ± SEM
range
279 ± 16.8
210–387
307 ± 19.9
57–886
301 ± 16
57–886
0.4668
Creatinin (µmol/l) (&) mean ± SEM
median
range
98.6 ± 21.9
64
51–290
153 ± 22.6
89
53–968
142 ± 18.5
85.5
51–968
0.2258
Plasma cell infiltration of the
bone marrow (%) (c)
mean ± SEM
range
26 ± 6.8
10–80
24 ± 2.9
0–90
25 ± 2.7
0–90
0.7711
Mean follow-up (months) 20.4 31.4 30.9
Progression yes / no 4/9 32/18 36/27 0.0566
Dead yes / no 1/12 23/27 24/39 0.0116
First line treatment + VAD
bortezomib/dex./cycloph.
bortezomib/dex.
thalidomide/dex.
melphalan/pred.
lenalidomide/dex.
1
2
2
0
0
0
6
3
15
2
15
2
7
5
17
2
15
2
Number of involved organs 1
2
3
≥4
8 (61%)
4 (31%)
1 (8%)
0
22 (44%)
15 (30%)
11 (22%)
2 (4%)
30 (48%)
19 (30%)
12 (19%)
2 (3%)
Involved organs heart
kidney
liver
nerve
various (X)
5 (38%)
7 (54%)
1 (8%)
4 (31%)
4 (31%)
33 (66%)
28 (56%)
4 (8%)
13 (26%)
15 (30%)
38 (60%)
35 (56%)
5 (8%)
17 (27%)
19 (30%)
Response to induction (") complete remission
partial remission
stable disease/progression disease
0
4
0
5
17
3
5
21
3
Revised Mayo stage (^) I
II
III
IV
2
5
1
0
0
3
2
4
2
8
3
4
×Troponin-T data were available from 23 patients, and °BNP data from 25 patients; §Information on β2microglobulin was available from 31 patients, and on albumin from 53
patients,;*Information on the light chain subtype was not available from 2 patients, yand on the light chain level from 26 patients; $information on the paraprotein value was
available from 29 patients, &on creatinine from 60 patients, and con the plasma cell infiltration in the bone marrow from 53 patients; "data on the response to induction
treatment was available from 34 patients, and ^sufficient information allowing classification according to the revised Mayo stage criteria was available from 17 patients;
Xincluded lung, intestine, spleen, larynx, or tongue. +VAD: vincristine, adriamycin, dexamethasone; dex: dexamethasone; pred: prednisone; cycloph: cyclophos-phamide.
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lower (0.015 μg/l vs 0.08 μg/l, p = 0.0279). Thus, a pos-
sible factor contributing to the improved outcome, in addi-
tion to the more intensive treatment, of patients receiving
HDCT/ASCT may be their better performance status and
superior cardiac function. Ultimately, patient cohorts with
matched characteristics within a sufficiently powered ran-
domised clinical trial will be necessary to define the impact
of the better performance status on outcome.
The retrospective character and the small number of pa-
tients in the HDCT/ASCT group limit the power of this
study. Nevertheless, these real-life observations may allow
some conclusions. Based on the differences in age and
troponin-T values in our two subgroups, our study confirms
current treatment algorithms recommending intensive
treatment to fit amyloidosis patients with limited organ
involvement and with clinically insignificant cardiac in-
volvement, whereas amyloidosis patients not meeting these
criteria should be treated with conventional chemotherapy
regimens. As with many other rare tumour types, further re-
search questions aiming to improve the treatment of amyl-
oidosis patients must be based on sufficiently large num-
bers of patients. Thus, an obvious step will be to extend this
single centre cohort to additional centres, ideally towards
the establishment of a Swiss cohort of AL-amyloidosis pa-
tients. Such an initiative is currently being initiated, and
it will hopefully be accompanied by the initiation of the
first clinical trials in Switzerland specifically focusing on
amyloidosis patients. This is of particular clinical relevance
since amyloidosis patients are usually excluded from trials
of multiple myeloma patients and treatment regimens for
these two groups of patients are similar.
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Figures (large format)
Figure 1A
Overall survival of all AL-amyloidosis patients. The median overall survival of the entire study population was 133 months. Twenty-four patients
died. X-axis indicates months, and Y-axis percent survival.
Figure 1B
Overall survival of patients treated with HDCT/ASCT (continuous line) versus conventional chemotherapy (dotted line). The HDCT/ASCT
showed a trend toward better overall survival (p = 0.0651). The HDCT/ASCT group had not yet reached median overall survival, whereas the
median overall survival of the conventional chemotherapy group was 53 months.
ASCT = autologous stem cell transplantation; HDCT = high-dose chemotherapy
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Figure 1C
Time to progression (TTP) of the entire study group. Median TTP was 39 months, and 36 patients had progression of their disease.
Figure 1D
Time to progression (TTP of) patients treated with HDCT/ASCT (continuous line) versus conventional chemotherapy regimens (dotted line). The
HDCT/ASCT group had not yet reached the median TTP; the TTP of the conventional chemotherapy group was 15 months (p = 0.248).ASCT =
autologous stem cell transplantation; HDCT = high-dose chemotherapy
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